biostudies-literatureMammen JJIndian Council of Medical Researche050571https://www.ebi.ac.uk/biostudies/studies/S-EPMC8491003biostudies-literatureUnknown11(10)<h4>Objective</h4>Large data on the clinical characteristics and outcome of COVID-19 in the Indian population are scarce. We analysed the factors associated with mortality in a cohort of moderately and severely ill patients with COVID-19 enrolled in a randomised trial on convalescent plasma.<h4>Design</h4>Secondary analysis of data from a Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease.<h4>Setting</h4>39 public and private hospitals across India during the study period from 22 April to 14 July 2020.<h4>Participants</h4>Of the 464 patients recruited, two were lost to follow-up, nine withdrew consent and two patients did not receive the intervention after randomisation. TBMJ openFactors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial.PMC8491003RFC No. ECD/NTF/20/2020-21/Covid Dated 23.07.2020Rupali PKumar VJindal AMukherjee ABhat SMani TKhambholja JRKumar SBhatnagar TTambe MZachariah ASharma AJain AAgarwal ASapkal GSingh NChatterjee PGurtoo AJeyaseelan LDaniel DSingh RPanjwani SJChander BTBabu KVSSharma NKhadke VKGokhale YAJoy MPatel TCLatha BBajpayee ASharma JAparna CYadav PDMalhotra PMurugesan MShrivastav ORasalam JEReddy DHChacko BDube SThomas LSuri AJha PRNatarajan MKaushal HBaldi MBarge VBahadur SBundas SKaulgud RSDosi RPeter JVUpadhyay KMammen JJKumar GKumar VSNagori IDua Sde Souza RfalseFactors associated with mortality among moderate and severe patients with COVID-19 in India: a secondary analysis of a randomised controlled trial.<h4>Objective</h4>Large data on the clinical characteristics and outcome of COVID-19 in the Indian population are scarce. We analysed the factors associated with mortality in a cohort of moderately and severely ill patients with COVID-19 enrolled in a randomised trial on convalescent plasma.<h4>Design</h4>Secondary analysis of data from a Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease.<h4>Setting</h4>39 public and private hospitals across India during the study period from 22 April to 14 July 2020.<h4>Participants</h4>Of the 464 patients recruited, two were lost to follow-up, nine withdrew consent and two patients did not receive the intervention after randomisation. T2021-01-01T00:00:00Z2021 Oct2025-04-19T05:03:40.101Z2022-02-11T11:47:52.138ZS-EPMC84910033460786510.1136/bmjopen-2021-050571